Asana, Inc. (NYSE: ASAN) targets $858m FY27 revenue as AI expansion and CFO shift signal strategic reset
Asana (NYSE: ASAN) targets up to $858M in FY27 revenue while expanding its AI platform and appointing a new CFO. What does this mean for investors?
Why Peter Thiel’s planned $280m stock sale could test Palantir Technologies Inc. (NYSE: PLTR) investor conviction
Peter Thiel files to sell $280M in Palantir Technologies Inc. shares. What it means for PLTR stock, valuation risk, and AI momentum. Read more.
When cloud meets conflict: What the Gulf drone strikes mean for Amazon Web Services
Drone strikes damage Amazon Web Services data centers in UAE and Bahrain. Explore what this means for Amazon.com, Inc. and global cloud risk.
Amazon cloud goes dark in UAE after data center struck during Iran missile offensive
Amazon Web Services reports UAE data center struck by objects, causing fire and multi-zone outage in Middle East Central 1 region amid Iran Gulf attacks.
What does Germain Turpin’s interim CEO role mean for Prime Drink Group’s next chapter?
Prime Drink Group appoints Germain Turpin as interim CEO. Discover what this leadership shift means for strategy, governance, and growth. Read more.
Why Delta Air Lines quietly became the most aggressive fleet buyer in U.S. aviation in under two months
Delta Air Lines orders 34 more Airbus A321neo jets in its third fleet deal in six weeks. What the buying spree means for DAL investors and U.S. rivals. Read more.
Is Fulgent Genetics rebuilding itself as a pathology-first diagnostics platform after losing a major customer?
Fulgent Genetics targets $350M 2026 revenue as pathology expansion reshapes its customer mix. Read how the strategy could stabilise growth.
How ALX Oncology Holdings Inc is repositioning its clinical strategy to achieve pivotal trial readiness by end-2026
ALX Oncology outlines its 2026 pivotal trial roadmap as ASPEN-09 expands and $150m funding extends runway. Read what changes next.
The drug that could dethrone Voxzogo: FDA clears Ascendis Pharma’s navepegritide alfa for achondroplasia
FDA approves Ascendis Pharma's navepegritide alfa for achondroplasia, intensifying competition with BioMarin's Voxzogo. Read what this means for the rare disease market.
Bigger than the Big Mac: What McDonald’s Corporation’s Big Arch Burger reveals about fast food economics
McDonald’s biggest U.S. burger ever is not just a menu launch. Find out how the Big Arch signals a deeper shift in fast food strategy.